GlassScriptPhysician profile
Richard Onysko
NPI 1679683239
$2,808.50
in general payments reported to CMS, 2019-2025
17 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $349 · 2023: $943 · 2024: $959 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493 · Consulting Fee: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.60 |
| Consulting Fee | $550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $729.95 | 2021-2024 | Aveir, Gallant, Merlin@Home |
| Novartis Pharmaceuticals Corporation | $634.54 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $290.64 | 2023-2024 | Inpefa |
| Amgen INC. | $185.73 | 2021-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $182.10 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.49 | 2024 | Jardiance |
| Medtronic, INC. | $152.42 | 2024 | Micra |
| Novo Nordisk INC | $121.81 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $71.39 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $58.19 | 2021-2023 | Farxiga, Wainua |
| Amarin Pharma, INC. | $42.62 | 2021 | |
| Boston Scientific Corporation | $39.24 | 2021-2024 | Emblem Mri S-Icd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.10 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $30.82 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $22.69 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2024 | |
| Astellas Pharma US INC | $17.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Onysko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.